Literature DB >> 27294095

Editorial on low-dose acetylsalicylic acid treatment and impact on short-term mortality in Staphylococcus aureus bloodstream infection: a propensity score-matched cohort study.

Christian Schoergenhofer1, Michael Schwameis1, Heimo Lagler1, Bernd Jilma1.   

Abstract

The manuscript "Low-Dose Acetylsalicylic Acid Treatment and Impact on Short-Term Mortality in Staphylococcus aureus (S. aureus) Bloodstream Infection: A propensity Score-Matched Cohort Study" published in Critical Care Medicine by Osthoff et al. reported an association of aspirin intake with a reduced short-term mortality. Direct anti-microbial effects of aspirin and its metabolite salicylate were suggested in preclinical studies. Especially intriguing is the inclusion of a control group with Escherichia coli (E. coli) blood stream infections in this study, in which aspirin was not associated with an improved outcome. However, as other observational studies also reported benefits of aspirin in critically ill patients, randomized trials are needed to confirm the effects of low-dose aspirin.

Entities:  

Keywords:  Aspirin; Escherichia coli (E. coli); Staphylococcus aureus (S. aureus); mortality

Year:  2016        PMID: 27294095      PMCID: PMC4885907          DOI: 10.21037/atm.2016.05.35

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  24 in total

Review 1.  Antiplatelet drugs.

Authors:  Gustav Born; Carlo Patrono
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

Review 2.  Cardiovascular pharmacology core reviews: aspirin.

Authors:  Michael A Gaglia; Leonardo Clavijo
Journal:  J Cardiovasc Pharmacol Ther       Date:  2013-09-19       Impact factor: 2.457

Review 3.  Lipoxins and aspirin-triggered lipoxins in resolution of inflammation.

Authors:  Mario Romano; Eleonora Cianci; Felice Simiele; Antonio Recchiuti
Journal:  Eur J Pharmacol       Date:  2015-04-18       Impact factor: 4.432

4.  Salicylic acid activates sigma factor B by rsbU-dependent and -independent mechanisms.

Authors:  Marco Palma; Arnold Bayer; Leon I Kupferwasser; Tammy Joska; Michael R Yeaman; Ambrose Cheung
Journal:  J Bacteriol       Date:  2006-08       Impact factor: 3.490

5.  Acetylsalicylic acid reduces vegetation bacterial density, hematogenous bacterial dissemination, and frequency of embolic events in experimental Staphylococcus aureus endocarditis through antiplatelet and antibacterial effects.

Authors:  L I Kupferwasser; M R Yeaman; S M Shapiro; C C Nast; P M Sullam; S G Filler; A S Bayer
Journal:  Circulation       Date:  1999-06-01       Impact factor: 29.690

6.  Effect of salicylic acid on invasion of human vascular endothelial cells by Staphylococcus aureus.

Authors:  Wan Beom Park; Sung-Han Kim; Jae Hyun Cho; Ji Hwan Bang; Hong Bin Kim; Nam Joong Kim; Myoung-don Oh; Kang Won Choe
Journal:  FEMS Immunol Med Microbiol       Date:  2006-11-09

7.  Salicylic acid diminishes Staphylococcus aureus capsular polysaccharide type 5 expression.

Authors:  Lucía P Alvarez; María S Barbagelata; Mariana Gordiola; Ambrose L Cheung; Daniel O Sordelli; Fernanda R Buzzola
Journal:  Infect Immun       Date:  2009-12-14       Impact factor: 3.441

8.  Salicylic acid attenuates virulence in endovascular infections by targeting global regulatory pathways in Staphylococcus aureus.

Authors:  Leon Iri Kupferwasser; Michael R Yeaman; Cynthia C Nast; Deborah Kupferwasser; Yan-Qiong Xiong; Marco Palma; Ambrose L Cheung; Arnold S Bayer
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

9.  Low-Dose Acetylsalicylic Acid Treatment and Impact on Short-Term Mortality in Staphylococcus aureus Bloodstream Infection: A Propensity Score-Matched Cohort Study.

Authors:  Michael Osthoff; Jan A Sidler; Botond Lakatos; Reno Frei; Marc Dangel; Maja Weisser; Manuel Battegay; Andreas F Widmer
Journal:  Crit Care Med       Date:  2016-04       Impact factor: 7.598

Review 10.  Pro-resolving lipid mediators are leads for resolution physiology.

Authors:  Charles N Serhan
Journal:  Nature       Date:  2014-06-05       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.